A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 4990-5008

  He, Yantao ^a   Liu, Sijiu ^a   Menon, Ambili ^b   Stanford, Stephanie ^c   Oppong, Emmanuel ^b   Gunawan, Andrea M ^a   Wu, Li ^a   Wu, Dennis J ^c   Barrios, Amy M ^d   Bottini, Nunzio ^c   Cato, Andrew C B ^b   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLOROPHENYL) 3 ETHYNYL 6 HYDROXYBENZOFURAN 5 CARBOXYLIC ACID; 2 [(1,1' BIPHENYL) 4 YL] 3 ETHYNYL 6 HYDROXYBENZOFURAN 5 CARBOXYLIC ACID; 2,2 DIMETHYL 6 (THIOPHEN 3 YLETHYNYL) 7 [4 (TRIFLUOROMETHOXY)PHENYL] 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 4 ONE; 2,2 DIMETHYL 7 (4 PHENOXYPHENYL) 6 [(TRIMETHYLSILYL)ETHYNYL] 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 4 ONE; 2,2 DIMETHYL 7 (NAPHTHALEN 1 YL) 6 [(TRIMETHYLSILYL)ETHYNYL] 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 4 ONE; 2,2 DIMETHYL 7 [4 (TRIFLUOROMETHOXY)PHENYL] 6 [(TRIMETHYLSILYL)ETHYNYL] 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 4 ONE; 3 [(3 CHLOROPHENYL)ETHYNYL] 2 [4 [2 (CYCLOPROPYLAMINO) 2 OXOETHOXY]PHENYL] 6 HYDROXYBENZOFURAN 5 CARBOXYLIC ACID; 3 [(3 CHLOROPHENYL)ETHYNYL] 6 HYDROXY 2 [4 (TRIFLUOROMETHOXY)PHENYL]BENZOFURAN 5 CARBOXYLIC ACID; 3 [(3,4 DICHLOROPHENYL)ETHYNYL) 6 HYDROXY 2 [4 (TRIFLUOROMETHOXY)PHENYL]BENZOFURAN 5 CARBOXYLIC ACID; 3 [[3 (CARBOXYMETHOXY)PHENYL]ETHYNYL] 6 HYDROXY 2 [4 (TRIFLUOROMETHOXY)PHENYL]BENZOFURAN 5 CARBOXYLIC ACID; 3 ETHYNYL 6 HYDROXY 2 (4 PHENOXYPHENYL)BENZOFURAN 5 CARBOXYLIC ACID; 3 ETHYNYL 6 HYDROXY 2 (NAPHTHALEN 1 YL)BENZOFURAN 5 CARBOXYLIC ACID; 3 ETHYNYL 6 HYDROXY 2 [4 (TRIFLUOROMETHOXY)PHENYL]BENZOFURAN 5 CARBOXYLIC ACID; 6 [(1,1' BIPHENYL) 4 YLETHYNYL] 7 METHOXY 2,2 DIMETHYL 4H BENZO[D][1,3]DIOXIN 4 ONE; 6 [(3 CHLOROPHENYL)ETHYNYL] 2,2 DIMETHYL 7 [4 (TRIFLUOROMETHOXY)PHENYL] 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 4 ONE; 6 [(3 CHLOROPHENYL)ETHYNYL] 7 METHOXY 2,2 DIMETHYL 4H BENZO[D][1,3]DIOXIN 4 ONE; 6 HYDROXY 3 (THIOPHEN 3 YLETHYNYL) 2 [4 (TRIFLUOROMETHOXY)PHENYL]BENZOFURAN 5 CARBOXYLIC ACID; 6 HYDROXY BENZOFURAN 5 CARBOXYLIC ACID DERIVATIVE; 7 (3 CHLOROPHENYL) 2,2 DIMETHYL 6 [(TRIMETHYLSILYL)ETHYNYL] 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 4 ONE; 7 [(1,1' BIPHENYL) 4 YL] 2,2 DIMETHYL 6 [(TRIMETHYLSILYL)ETHYNYL] 4H[1,3]DIOXINO[5,4 F]BENZOFURAN 4 ONE; 7 METHOXY 2,2 DIMETHYL 6 (NAPHTHALEN 1 YLETHYNYL) 4H BENZO[D][1,3]DIOXIN 4 ONE; 7 METHOXY 2,2 DIMETHYL 6 [(4 PHENOXYPHENYL)ETHYNYL] 4H BENZO[D][1,3]DIOXIN 4 ONE; 7 METHOXY 2,2 DIMETHYL 6 [[4 (TRIFLUOROMETHOXY)PHENYL]ETHYNYL] 4H BENZO[D][1,3]DIOXIN 4 ONE; LYMPHOID SPECIFIC TYROSINE PHOSPHATASE INHIBITOR; METHYL 2 [3 (6 IODO 2,2 DIMETHYL 4 OXO 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 7 YL)PHENOXY]ACETATE; METHYL 2 [3 [(2,2 FIMETHYL 4 OXO 7 [4 (TRIFLUOROMETHOXY)PHENYL] 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 6 YL)ETHYNYL]PHENOXY]ACETATE; METHYL 2 [3 [(7 METHOXY 2,2 DIMETHYL 4 OXO 4H BENZO[D][1,3]DIOXIN 6 YL)ETHYNYL]PHENOXY]ACETATE; METHYL 2 [3 [6 [(3 CHLOROPHENYL)ETHYNYL] 2,2 DIMETHYL 4 OXO 4H [1,3]DIOXINO[5,4 F]BENZOFURAN 7 YL]PHENOXY]ACETATE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; IC 50; LIGAND BINDING; MAST CELL; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; SYNTHESIS; T LYMPHOCYTE; X RAY CRYSTALLOGRAPHY;

ANAPHYLAXIS; ANIMALS; AUTOIMMUNE DISEASES; CARBOXYLIC ACIDS; DOWN-REGULATION; FEMALE; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MAST CELLS; MICE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SMALL MOLECULE LIBRARIES;

EID: 84879581867     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400248c     Document Type: Article

References (64)

1. Hunter, T. Tyrosine phosphorylation: thirty years and counting Curr. Opin. Cell Biol. 2009, 21, 140-146
2. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease Nature Rev. Mol. Cell Biol. 2006, 7, 833-846
3. Cohen, P.; Alessi, D. R. Kinase Drug Discovery-What's Next in the Field? ACS Chem. Biol. 2013, 8, 96-104
4. Zhang, Z.-Y. Protein Tyrosine Phosphatases: Prospects for Therapeutics Curr. Opin. Chem. Biol. 2001, 5, 416-423
5. Julien, S. G.; Dubé, N.; Hardy, S.; Tremblay, M. L. Inside the human cancer tyrosine phosphatome Nature Rev. Cancer 2011, 11, 35-49
6. Cohen, S.; Dadi, H.; Shaoul, E.; Sharfe, N.; Roifman, C. M. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp Blood 1999, 93, 2013-2024
7. Gjorloff-Wingren, A.; Saxena, M.; Williams, S.; Hammi, D.; Mustelin, T. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP Eur. J. Immunol. 1999, 29, 3845-3854
8. Cloutier, J.-F.; Veillette, A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase J. Exp. Med. 1999, 189, 111-121
9. Wu, J.; Katrekar, A.; Honigberg, L. A.; Smith, A. M.; Conn, M. T.; Tang, J.; Jeffery, D.; Mortara, K.; Sampang, J.; Williams, S. R.; Buggy, J.; Clark, J. M. Identification of substrates of human protein-tyrosine phosphatase PTPN22 J. Biol. Chem. 2006, 281, 11002-11010
10. Bottini, N.; Musumeci, L.; Alonso, A.; Rahmouni, S.; Nika, K.; Rostamkhani, M.; MacMurray, J.; Meloni, G. F.; Lucarelli, P.; Pellecchia, M.; Eisenbarth, G. S.; Comings, D.; Mustelin, T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes Nature Genet. 2004, 36, 337-338
11. Begovich, A. B.; Carlton, V. E.; Honigberg, L. A.; Schrodi, S. J.; Chokkalingam, A. P.; Alexander, H. C.; Ardlie, K. G.; Huang, Q.; Smith, A. M.; Spoerke, J. M.; Conn, M. T.; Chang, M.; Chang, S. Y.; Saiki, R. K.; Catanese, J. J.; Leong, D. U.; Garcia, V. E.; McAllister, L. B.; Jeffery, D. A.; Lee, A. T.; Batliwalla, F.; Remmers, E.; Criswell, L. A.; Seldin, M. F.; Kastner, D. L.; Amos, C. I.; Sninsky, J. J.; Gregersen, P. K. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis Am. J. Hum. Genet. 2004, 75, 330-337
12. Carlton, V. E.; Hu, X.; Chokkalingam, A. P.; Schrodi, S. J.; Brandon, R.; Alexander, H. C.; Chang, M.; Catanese, J. J.; Leong, D. U.; Ardlie, K. G.; Kastner, D. L.; Seldin, M. F.; Criswell, L. A.; Gregersen, P. K.; Beasley, E.; Thomson, G.; Amos, C. I.; Begovich, A. B. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis Am. J. Hum. Genet. 2005, 77, 567-581
13. Smyth, D.; Cooper, J. D.; Collins, J. E.; Heward, J. M.; Franklyn, J. A.; Howson, J. M.; Vella, A.; Nutland, S.; Rance, H. E.; Maier, L.; Barratt, B. J.; Guja, C.; Ionescu-Tirgoviste, C.; Savage, D. A.; Dunger, D. B.; Widmer, B.; Strachan, D. P.; Ring, S. M.; Walker, N.; Clayton, D. G.; Twells, R. C.; Gough, S. C.; Todd, J. A. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus Diabetes 2004, 53, 3020-3023
14. Kyogoku, C.; Langefeld, C. D.; Ortmann, W. A.; Lee, A.; Selby, S.; Carlton, V. E.; Chang, M.; Ramos, P.; Baechler, E. C.; Batliwalla, F. M.; Novitzke, J.; Williams, A. H.; Gillett, C.; Rodine, P.; Graham, R. R.; Ardlie, K. G.; Gaffney, P. M.; Moser, K. L.; Petri, M.; Begovich, A. B.; Gregersen, P. K.; Behrens, T. W. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE Am. J. Hum. Genet. 2004, 75, 504-507
15. Vandiedonck, C.; Capdevielle, C.; Giraud, M.; Krumeich, S.; Jais, J. P.; Eymard, B.; Tranchant, C.; Gajdos, P.; Garchon, H. J. Association of the PTPN22 R620W polymorphism with autoimmune myasthenia gravis Ann. Neurol. 2006, 59, 404-407
16. Greve, B.; Hoffmann, P.; Illes, Z.; Rozsa, C.; Berger, K.; Weissert, R.; Melms, A. The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibodypositive myasthenia gravis Hum. Immunol. 2009, 70, 540-542
17. Canton, I.; Akhtar, S.; Gavalas, N. G.; Gawkrodger, D. J.; Blomhoff, A.; Watson, P. F.; Weetman, A. P.; Kemp, E. H. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo Genes Immun. 2005, 6, 584-587
18. LaBerge, G. S.; Bennett, D. C.; Fain, P. R.; Spritz, R. A. PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not J. Invest. Dermatol. 2008, 128, 1757-1762
19. Burn, G. L.; Svensson, L.; Sanchez-Blanco, C.; Saini, M.; Cope, A. P. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett. 2011, 585, 3689-3698
20. Vang, T.; Congia, M.; Macis, M. D.; Musumeci, L.; Orru, V.; Zavattari, P.; Nika, K.; Tautz, L.; Tasken, K.; Cucca, F.; Mustelin, T.; Bottini, N. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant Nature Genet. 2005, 37, 1317-1319
21. Rieck, M.; Arechiga, A.; Onengut-Gumuscu, S.; Greenbaum, C.; Concannon, P.; Buckner, J. H. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes J. Immunol. 2007, 179, 4704-4710
22. Arechiga, A. F.; Habib, T.; He, Y.; Zhang, X.; Zhang, Z.-Y.; Funk, A.; Buckner, J. H. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling J. Immunol. 2009, 182, 3343-3347
23. Habib, T.; Funk, A.; Rieck, M.; Brahmandam, A.; Dai, X.; Panigrahi, A. K.; Luning Prak, E. T.; Meyer-Bahlburg, A.; Sanda, S.; Greenbaum, C.; Rawlings, D. J.; Buckner, J. H. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant J Immunol. 2012, 188, 487-496
24. Vang, T.; Liu, W. H.; Delacroix, L.; Wu, S.; Vasile, S.; Dahl, R.; Yang, L.; Musumeci, L.; Francis, D.; Landskron, J.; Tasken, K.; Tremblay, M. L.; Lie, B. A.; Page, R.; Mustelin, T.; Rahmouni, S.; Rickert, R. C.; Tautz, L. LYP inhibits T-cell activation when dissociated from CSK Nature Chem. Biol. 2012, 8, 437-446
25. Orrú, V.; Tsai, S. J.; Rueda, B.; Fiorillo, E.; Stanford, S. M.; Dasgupta, J.; Hartiala, J.; Zhao, L.; Ortego-Centeno, N.; D'Alfonso, S.; Italian Collaborative Group; Arnett, F. C.; Wu, H.; Gonzalez-Gay, M. A.; Tsao, B. P.; Pons-Estel, B.; Alarcon-Riquelme, M. E.; He, Y.; Zhang, Z.-Y.; Allayee, H.; Chen, X. S.; Martin, J.; Bottini, N. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus Hum. Mol. Genet. 2009, 18, 569-579
26. Brownlie, R. J.; Miosge, L. A.; Vassilakos, D.; Svensson, L. M.; Cope, A.; Zamoyska, R. Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function Sci. Signal. 2013, 5, ra87
27. Zheng, P.; Kissler, S. PTPN22 Silencing in the NOD Model Indicates the Type 1 Diabetes-Associated Allele Is Not a Loss-of-Function Variant Diabetes 2012, 62, 896-904
28. Yu, X.; Sun, J. P.; He, Y.; Guo, X. L.; Liu, S.; Zhou, B.; Hudmon, A.; Zhang, Z.-Y. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 19767-19772
29. Xie, Y. L.; Liu, Y. D.; Gong, G. L.; Rinderspacher, A.; Deng, S. X.; Smith, D. H.; Toebben, U.; Tzilianos, E.; Branden, L.; Vidovic, D.; Chung, C.; Schurer, S.; Tautz, L.; Landry, D. W. Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase Bioorg. Med. Chem. Lett. 2008, 18, 2840-2844
30. Wu, S.; Bottini, M.; Rickert, R. C.; Mustelin, T.; Tautz, L. In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation ChemMedChem 2009, 4, 440-444
31. Karver, M. R.; Krishnamurthy, D.; Kulkarni, R. A.; Bottini, N.; Barrios, A. M. Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes J. Med. Chem. 2009, 52, 6912-6918
32. Karver, M. R.; Krishnamurthy, D.; Bottini, N.; Barrios, A. M. Gold(I) phosphine mediated selective inhibition of lymphoid tyrosine phosphatase J. Inorg. Biochem. 2010, 104, 268-273
33. Vidović, D.; Xie, Y.; Rinderspacher, A.; Deng, S. X.; Landry, D. W.; Chung, C.; Smith, D. H.; Tautz, L.; Schürer, S. C. Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype J. Comput.-Aided. Mol. Des. 2011, 25, 873-883
34. Stanford, S. M.; Krishnamurthy, D.; Falk, M. D.; Messina, R.; Debnath, B.; Li, S.; Liu, T.; Kazemi, R.; Dahl, R.; He, Y.; Yu, X.; Chan, A. C.; Zhang, Z.-Y.; Barrios, A. M.; Woods, V. L., Jr.; Neamati, N.; Bottini, N. Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells J. Med. Chem. 2011, 54, 1640-1654
35. Vang, T.; Xie, Y.; Liu, W. H.; Vidović, D.; Liu, Y.; Wu, S.; Smith, D. H.; Rinderspacher, A.; Chung, C.; Gong, G.; Mustelin, T.; Landry, D. W.; Rickert, R. C.; Schürer, S. C.; Deng, S. X.; Tautz, L. Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids J. Med. Chem. 2011, 54, 562-571
36. He, Y.; Zeng, L.-F.; Yu, Z.-H.; He, R.; Liu, S.; Zhang, Z.-Y. Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors Bioorg. Med. Chem. 2012, 20, 1940-1946
37. Puius, Y. A.; Zhao, Y.; Sullivan, M.; Lawrence, D. S.; Almo, S. C.; Zhang, Z.-Y. Identification of a Second Aryl Phosphate-Binding Site in Protein-Tyrosine Phosphatase 1B: A Paradigm for Inhibitor Design Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 13420-13425
38. Zhang, Z.-Y. Protein Tyrosine Phosphatases: Structure and Function, Substrate Specificity, and Inhibitor Development Annu. Rev. Pharmacol. Toxicol. 2002, 42, 209-234
39. He, Y.; Xu, J.; Yu, Z.-H.; Gunawan, A. M.; Wu, L.; Wang, L.; Zhang, Z.-Y. Discovery and evaluation of novel inhibitors of Mycobacterium protein tyrosine phosphatase B from the 6-hydroxy-benzofuran-5-carboxylic acid scaffold J. Med. Chem. 2013, 56, 832-842
40. Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N.; Filippakopoulos, P.; Alfano, I.; Savitsky, P.; Burgess-Brown, N. A.; Muller, S.; Knapp, S. Large-scale structural analysis of the classical human protein tyrosine phosphatome Cell 2009, 136, 352-363
41. Sarmiento, M.; Wu, L.; Keng, Y. F.; Song, L.; Luo, Z.; Huang, Z.; Wu, G.-Z.; Yuan, A. K.; Zhang, Z.-Y. Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B J. Med. Chem. 2000, 43, 146-155
42. Liang, F.; Huang, Z.; Lee, S.-Y.; Liang, J.; Ivanov, M. I.; Alonso, A.; Bliska, J. B.; Lawrence, D. S.; Mustelin, T.; Zhang, Z.-Y. Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague J. Biol. Chem. 2003, 278, 41734-41741
43. Zhang, X.; He, Y.; Liu, S.; Yu, Z.; Jiang, Z.-X.; Yang, Z.; Dong, Y.; Nabinger, S. C.; Wu, L.; Gunawan, A. M.; Wang, L.; Chan, R. J.; Zhang, Z.-Y. Salicylic acid-based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) J. Med. Chem. 2010, 53, 2482-2493
44. Sarmiento, M.; Puius, Y. A.; Vetter, S. W.; Keng, Y. F.; Wu, L.; Zhao, Y.; Lawrence, D. S.; Almo, S. C.; Zhang, Z.-Y. Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition Biochemistry 2000, 39, 8171-8179
45. Bottini, N.; Vang, T.; Cucca, F.; Mustelin, T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases Semin. Immunol. 2006, 18, 207-213
46. Cosulich, M. E.; Rubartelli, A.; Risso, A.; Cozzolino, F.; Bargellesi, A. Functional characterization of an antigen involved in an early step of T-cell activation Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 4205-4209
47. Moran, A. E.; Holzapfel, K. L.; Xing, Y.; Cunningham, N. R.; Maltzman, J. S.; Punt, J.; Hogquist, K. A. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse J. Exp. Med. 2011, 208, 1279-1289
48. Peavy, R. D.; Metcalfe, D. D. Understanding the mechanisms of anaphylaxis Curr. Opin. Allergy Clin. Immunol. 2008, 8, 310-315
49. Bischoff, S. C. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data Nature Rev. Immunol. 2007, 7, 93-104
50. Griffiths, G. M. Secretory lysosomes-a special mechanism of regulated secretion in haemopoietic cells Trends Cell Biol. 1996, 6, 329-332
51. Obiri, D. D.; Flink, N.; Maier, J. V.; Neeb, A.; Maddalo, D.; Thiele, W.; Menon, A.; Stassen, M.; Kulkarni, R. A.; Garabedian, M. J.; Barrios, A. M.; Cato, A. C. PEST-domain-enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in mice Allergy 2012, 67, 175-182
52. Gilfillan, A. M.; Metcalfe, D. D.; Austin, S. J. Mast cell biology: introduction and overview. Mast Cell Biology: Contemporary and Emerging Topics; Gilfillan, A. M.; Metcalfe, D. D., Eds.; Landes Bioscience: Austin, TX, 2011; pp 2-13.
53. Schorpp, M.; Jager, R.; Schellander, K.; Schenkel, J.; Wagner, E. F.; Weiher, H.; Angel, P. The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice Nucleic Acids Res. 1996, 24, 1787-1788
54. Spurg, A.; Waldvogel, S. R. High-Yielding Cleavage of (Aryloxy)acetates Eur. J. Org. Chem. 2008, 2008, 337-342
55. Minor, W.; Cymborowski, M.; Otwinowski, Z.; Chruszcz, M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes Acta. Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 859-866
56. Navaza, J. AMoRe: an automated package for molecular replacement Acta. Crystallogr., Sect. A: Found. Crystallogr. 1994, 50, 157-163
57. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: a new software suite for macromolecular structure determination Acta. Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921
58. Brünger, A. T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures Nature 1992, 355, 472-475
59. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improvedmethods for building protein models in electron density maps and the location of errors in these models Acta. Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 110-119
60. Shaw, J. P.; Utz, P. J.; Durand, D. B.; Toole, J. J.; Emmel, E. A.; Crabtree, G. R. Identification of a putative regulator of early T cell activation genes Science 1988, 241, 202-205
61. Kassel, O.; Sancono, A.; Krätzschmar, J.; Kreft, B.; Stassen, M.; Cato, A. C. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1 EMBO J. 2001, 20, 7108-7116
62. Weiss, A.; Stobo, J. D. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line J. Exp. Med. 1984, 160, 1284-1299
63. Hasegawa, K.; Martin, F.; Huang, G.; Tumas, D.; Diehl, L.; Chan, A. C. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells Science 2004, 303, 685-689
64. Maier, J. V.; Brema, S.; Tuckermann, J.; Herzer, U.; Klein, M.; Stassen, M.; Moorthy, A.; Cato, A. C. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids Mol. Endocrinol. 2007, 21, 2663-2671